3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
1
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
2
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
38
Specimen Handling
37
Magnetic Resonance Spectroscopy
26
Biopsy
26
Cyclophosphamide
25
Carboplatin
25
fludarabine
21
Nivolumab
20
Gemcitabine
18
Dexamethasone
18
Paclitaxel
15
Rituximab
13
Bevacizumab
13
Pemetrexed
12
Docetaxel
12
atezolizumab
11
Cisplatin
11
Lenalidomide
10
Ipilimumab
10
Fulvestrant
10
venetoclax
9
Prednisone
9
Oxaliplatin
9
olaparib
8
fludarabine phosphate
8
belantamab mafodotin
8
Temozolomide
8
Injections
8
Fluorouracil
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
R-CHOP protocol
×
30 days
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled
NCT04542824
2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-05-05
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled